trial · primary record
Enfortumab vedotin
Urothelial Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 390 |
| Primary completion | 2032-02-29 |
| Primary endpoint | Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR) |
| Registry ID | NCT07566156 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:42:58.969Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07566156
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.